Longeveron

Longeveron is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs. The company's lead investigational product is Lomecel-B™, an allogeneic medicinal signaling cell (MSC) therapy derived from the bone marrow of young, healthy adult donors. Lomecel-B™ has multiple potential mechanisms of action, including pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects, offering broad potential applications across a range of disease areas.